COMPARISON OF THE DYNAMICS OF THE CONSUMPTION OF HYPOGLYCEMIC MEDICINES IN UKRAINE AND SOME EUROPEAN COUNTRIES
DOI:
https://doi.org/10.11603/2312-0967.2023.4.14239Keywords:
type 2 diabetes, hypoglycemic agents, pharmaceutical market, ATC/DDD-methodology consumption volumes, comparison of consumption volumes, Ukraine, Norway, EstoniaAbstract
The aim of the work. Analysis of the assortment (for 2020-2022) and consumption volumes (for 2020-2021) of single-component hypoglycemic drugs (HGP) on the pharmaceutical market of Ukraine and comparison of HGP consumption indicators with data from European countries - Estonia and Norway.
Materials and Methods. To analyze the assortment and consumption of HGP in the pharmaceutical market of Ukraine, the State Register of Medicinal Products of Ukraine, Compendium online and data from the analytical research of the pharmaceutical market "Proxima Research" of the company "Morion" were used. Consumption studies were conducted according to the ATC/DDD methodology recommended by WHO.
Results and Discussion. The range of pharmaceutical products on the pharmaceutical market of Ukraine for 2020-2022 was quite wide - 136-141 assortment items of drugs mainly of domestic manufacturers (53.7-59.0%) based on 14 INNs. These drugs had a wide range of prices, which allows to optimize costs for the treatment of patients with type 2 diabetes. Metformin preparations from the group of biguanides (53.0-55.4%) and sulfonylureas (33.0-34.6%) took the largest share of the market in 2022. The consumption of HGP in Ukraine was high and varied from 22.21 DID in 2020 to 23.77 DID in 2021. The largest volumes of consumption fell on drugs of the groups of biguanides and derivatives of sulfonylureas, which is associated with their clinical effectiveness, low cost, the large number of generic drugs on the market, as well as the availability of the Affordable Medicines reimbursement program, which includes metformin, glibenclamide, and gliclazide. In Ukraine, compared to Norway and Estonia, the new effective classes of glucagon-like peptide-1 receptor antagonists and dipeptidyl peptidase-4 inhibitors, which are included in the modern international recommendations of the American Diabetes Association and the European Association for the Study of Diabetes Mellitus, are used rather little.
Conclusions. The peculiarities of the product range for 2020-2022 and the consumption of HGP in Ukraine for 2020-2021 have been established. During the period of the study, a trend towards an increase in the number of domestic drugs on the market and an increase in the overall level of consumption in 2021 compared to 2020 was noted. In order to comply with modern according to international recommendations for the treatment of patients with type 2 diabetes mellitus, it is appropriate to include new classes of drugs (GLP-1 and DPP-4) in the State Reimbursement Program "Affordable Medicines".
References
IDF Diabetes Atlas 2021 – 10th edition. [Internet]; 2021 [cited 2023 Nov 19]. Available from: https://diabetesatlas.com.ua/ua/v-ukrayini-2-mln-325-tys-lyudey-z-diabetom
International Diabetes Federation. Facts & figures. [Internet]; [cited 2023 Nov 16]. Available from: http://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html
Rак SО. Nеіnfekciyna еpidemiya tsukrovogo diabetu. Меdsestrinstvo. 2019;(3): 42-4.
American Diabetes Association Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019;42(1): 34-45. DOI: https://doi.org/10.2337/dc19-S004
Likuvannia hiperhlikemii pry tsukrovomu diabeti 2 typu: konsensusnyi zvit ADA/EASD Health-ua.com. [Internet]; 29.04.2021 [cited 2023 Nov 18]. Available from: https://health-ua.com/article/71068-lkuvannya-gperglkem-pri-tcukrovomu-dabet-2-tipu-konsensusnij-zvt-ADAEASD-206.
Chekman IS, Bondur VV. Farmakoterapiia tsukrovoho diabetu 2 typu: kliniko-farmakolohichni aspekty. Zdorovia Ukrainy. 2015;2(7):10-1.
Savych A, Pavliuk B. Marketynhovyi analiz farmatsevtychnoho rynku antydiabetychnykh likarskykh zasobiv v Ukraini. Aktualni pytannia farmatsevtychnoi i medychnoi nauky ta praktyky. 2022;15(1):80-5. DOI: https://doi.org/10.14739/2409-2932.2022.1.252509
Iakovlieva LV, Yakovlieva AK, Berdnyk OH. Analiz obsiahu spozhyvannia peroralnykh tsukroznyzhuvalnykh likarskykh zasobiv protiahom 2014-2017 rokiv na farmatsevtychnomu rynku Ukrainy. Sotsialna farmatsiia v okhoroni zdorovia. 2018;4(2):29-36. DOI: https://doi.org/10.24959/sphhcj.18.113
Kostrubov OO, Tkachova OV. Analiz obsiahiv spozhyvannia peroralnykh hipohlikemichnykh zasobiv na farmatsevtychnomu rynku. Vid eksperymentalnoi ta klinichnoi patofiziolohii do dosiahnen suchasnoi medytsyny ifarmatsii; 2022 trav. 19. Kharkiv. Kharkiv : NFaU; 2022. р. 197.
WHO Collaborating Centre for Drug Statistics Methodology; Guidelines for ATC classification and DDD assignment 2020. Oslo, Norway; 2019. 249 р.
Derzhavna sluzhba statystyky Ukrainy. [Internet]; 2022 [cited 2023 Nov 02]. Available from: www.ukrstat.gov.ua
Estonian Statistics on Medicines. [Internet]; 2022 [cited 2023 Nov 12]. Available from: https://ravimiamet.ee/en/statistics/statistical-yearbooks
Drug Consumption in Norway 2017-2021. Data from Norwegian Drug Wholesales Statistics and the Norwegian Prescription Database. [Internet]; 2022 [cited 2023 Nov 11]. Available from: https://www.fhi.no/contentassets/1b4b603c4ecf410588d584d5062cc9b8/legemiddelforbruket-i-norge-20172021.pdf
Reiestr likarskykh zasobiv, yaki pidliahaiut reimbursatsii za prohramoiu derzhavnykh harantii medychnoho obsluhovuvannia naselennia, stanom na 14 liutoho 2023 roku. [Internet]; 2022 [cited 2023 Nov 05]. Available from: https://www.apteka.ua/article/659109
Analiz systemy likuvannia ta rozrakhunok ekonomichnykh vtrat vid tsukrovoho diabetu v Ukraini. [Internet]; 2020. [cited 2023 Nov 19]. Available from: https://kse.ua/ua/kse-research/analiz-sistemi-likuvannya-ta-rozrahunok-ekonomichnih-vtrat-vid-tsukrovogo-diabetu-v-ukrayini/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pharmaceutical Review / Farmacevtičnij časopis
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The authors who publish their materials in this journal agree with the following terms:
- Authors reserve the right to authorship of their work and assign to the journal the right to first publish this work under the terms of the Creative Commons Attribution License, which allows other persons to freely distribute the published work with a mandatory reference to the authors of original work and the first publication of work in this journal
. - Authors have the right to make independent extra-exclusive work agreements in the form they are published by this journal (for example, posting work in an electronic repository of an institution or publishing as part of a monograph), provided that the link to the first publication of the work in this journal is maintained.
Journal policy allows and encourages publication of manuscripts on the Internet (for example, in institutions repositories or on personal websites), both before the publication of this manuscript and during its editorial review, as it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the citation of the published work (see The Effect of Open Access).
